Study of gemcitabine in end-stage liver disease with sepsis
10.3969/j.issn.1673-9701.2024.20.023
- VernacularTitle:吉粒芬治疗终末期肝病合并脓毒血症临床疗效及免疫学机制研究
- Author:
Rui WU
1
;
Yunlei XIAO
;
Xiaoqing FU
Author Information
1. 杭州市西溪医院重症肝病科,浙江杭州 310023
- Keywords:
End-stage liver disease;
Sepsis;
Recombinant human granulocyte colony-stimulating factor
- From:
China Modern Doctor
2024;62(20):104-107,112
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect and prognosis of recombinant human granulocyte colony-stimulating factor(rhG-CSF)in end-stage liver disease(ESLD)with sepsis.Methods Ninety patients with ESLD complicated with sepsis from January 2022 to December 2023 were selected and randomly divided into rhG-CSF group,thymosin group and control group,with 30 cases each.Compare the liver function,cytokine levels,treatment efficacy,complications,and ESLD model(MELD)scoring system before and after treatment among three groups.Results The total effective rate of rhG-CSF group was 96.67％,which was significantly higher than the other two groups,and the difference was statistically significant(P＜0.05).After treatment,the liver function,cytokine levels,and immune function recovery of the rhG-CSF group and thymosin group were better than that of control group,with statistical significance(P＜0.05).After 12 weeks of treatment and follow-up,the least complications and the lowest mortality rate in the rhG-CSF group.Conclusion The clinical efficacy of rhG-CSF as an adjuvant therapy for ESLD complicated with sepsis is excellent,which can enhance anti-infection ability and improve prognosis.
